Caris Life Sciences, Inc. (NASDAQ: CAI) Stock Competitors & Peer Comparison
See CAI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CAI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CAI | $24.34 | +1.25% | 6.9B | 68.39 | $0.36 | N/A |
| VRTX | $515.44 | +0.17% | 130.8B | 27.09 | $19.03 | N/A |
| REGN | $781.49 | -1.48% | 80.5B | 17.13 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $984.39 | +0.04% | 61.2B | 88.84 | $11.08 | N/A |
| MRNA | $143.97 | +5.38% | 57.1B | -17.67 | -$8.15 | N/A |
| RVMDW | $11.29 | +2.08% | 44.2B | -1.28 | -$8.82 | N/A |
| RVMD | $203.77 | +0.21% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $346.51 | +1.38% | 37B | 61.01 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CAI vs VRTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, VRTX has a market cap of 130.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while VRTX trades at $515.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas VRTX's P/E ratio is 27.09. In terms of profitability, CAI's ROE is +0.19%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CAI is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CAI vs REGN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while REGN trades at $781.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas REGN's P/E ratio is 17.13. In terms of profitability, CAI's ROE is +0.19%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CAI is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for CAI.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CAI vs VRNA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CAI's ROE is +0.19%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CAI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CAI vs ARGX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ARGX has a market cap of 61.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ARGX trades at $984.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ARGX's P/E ratio is 88.84. In terms of profitability, CAI's ROE is +0.19%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, CAI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
CAI vs MRNA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MRNA has a market cap of 57.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MRNA trades at $143.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MRNA's P/E ratio is -17.67. In terms of profitability, CAI's ROE is +0.19%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CAI is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for CAI.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CAI vs RVMDW Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RVMDW has a market cap of 44.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RVMDW trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, CAI's ROE is +0.19%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, CAI is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for CAI.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CAI vs RVMD Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RVMD trades at $203.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RVMD's P/E ratio is -23.10. In terms of profitability, CAI's ROE is +0.19%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, CAI is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for CAI.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
CAI vs SGEN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CAI's ROE is +0.19%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CAI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
CAI vs ONC Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ONC has a market cap of 37B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ONC trades at $346.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ONC's P/E ratio is 61.01. In terms of profitability, CAI's ROE is +0.19%, compared to ONC's ROE of +0.14%. Regarding short-term risk, CAI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CAI vs ALNY Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ALNY has a market cap of 33.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ALNY trades at $248.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ALNY's P/E ratio is 44.81. In terms of profitability, CAI's ROE is +0.19%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CAI is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CAI vs ROIV Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ROIV has a market cap of 29.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ROIV trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ROIV's P/E ratio is -38.82. In terms of profitability, CAI's ROE is +0.19%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, CAI is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
CAI vs INSM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, INSM has a market cap of 28B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while INSM trades at $129.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas INSM's P/E ratio is -31.49. In terms of profitability, CAI's ROE is +0.19%, compared to INSM's ROE of -1.11%. Regarding short-term risk, CAI is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for CAI.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
CAI vs INCY Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while INCY trades at $121.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas INCY's P/E ratio is 16.33. In terms of profitability, CAI's ROE is +0.19%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CAI is similarly volatile compared to INCY. This indicates similar risk in terms of short-term price fluctuations for CAI.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CAI vs BNTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BNTX trades at $96.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BNTX's P/E ratio is -12.54. In terms of profitability, CAI's ROE is +0.19%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, CAI is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CAI vs UTHR Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, UTHR has a market cap of 21.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while UTHR trades at $497.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas UTHR's P/E ratio is 17.79. In terms of profitability, CAI's ROE is +0.19%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, CAI is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for CAI.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CAI vs BGNE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CAI's ROE is +0.19%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, CAI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
CAI vs GMAB Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, GMAB has a market cap of 19.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while GMAB trades at $32.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas GMAB's P/E ratio is 24.47. In terms of profitability, CAI's ROE is +0.19%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CAI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CAI.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CAI vs DNA-WT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CAI's ROE is +0.19%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, CAI is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CAI vs ASND Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ASND trades at $263.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ASND's P/E ratio is -108.89. In terms of profitability, CAI's ROE is +0.19%, compared to ASND's ROE of +1.90%. Regarding short-term risk, CAI is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CAI vs NBIX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while NBIX trades at $156.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas NBIX's P/E ratio is 22.57. In terms of profitability, CAI's ROE is +0.19%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CAI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CAI vs JAZZ Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while JAZZ trades at $245.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas JAZZ's P/E ratio is 9.16. In terms of profitability, CAI's ROE is +0.19%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, CAI is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CAI.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CAI vs BBIO Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BBIO trades at $72.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BBIO's P/E ratio is -19.37. In terms of profitability, CAI's ROE is +0.19%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, CAI is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for CAI.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CAI vs EXEL Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while EXEL trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas EXEL's P/E ratio is 16.03. In terms of profitability, CAI's ROE is +0.19%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, CAI is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for CAI.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CAI vs SMMT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while SMMT trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas SMMT's P/E ratio is -15.67. In terms of profitability, CAI's ROE is +0.19%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CAI is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CAI vs HALO Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while HALO trades at $107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas HALO's P/E ratio is 20.00. In terms of profitability, CAI's ROE is +0.19%, compared to HALO's ROE of +1.81%. Regarding short-term risk, CAI is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for CAI.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CAI vs BMRN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BMRN trades at $65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BMRN's P/E ratio is 31.58. In terms of profitability, CAI's ROE is +0.19%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, CAI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CAI vs KRTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CAI's ROE is +0.19%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CAI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CAI vs MDGL Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MDGL trades at $534.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MDGL's P/E ratio is -41.76. In terms of profitability, CAI's ROE is +0.19%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CAI is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for CAI.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CAI vs ARWR Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ARWR has a market cap of 11.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ARWR trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ARWR's P/E ratio is -36.82. In terms of profitability, CAI's ROE is +0.19%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, CAI is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CAI vs AXSM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while AXSM trades at $220.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas AXSM's P/E ratio is -57.64. In terms of profitability, CAI's ROE is +0.19%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, CAI is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for CAI.Check AXSM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CAI vs TECH Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TECH trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TECH's P/E ratio is 37.18. In terms of profitability, CAI's ROE is +0.19%, compared to TECH's ROE of +0.09%. Regarding short-term risk, CAI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CAI vs RNAM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CAI's ROE is +0.19%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CAI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RNAM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CAI vs KRYS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while KRYS trades at $347.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas KRYS's P/E ratio is 43.48. In terms of profitability, CAI's ROE is +0.19%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CAI is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CAI vs RXDX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CAI's ROE is +0.19%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CAI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CAI vs PTGX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PTGX trades at $148.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PTGX's P/E ratio is 143.86. In terms of profitability, CAI's ROE is +0.19%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, CAI is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CAI vs KYMR Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while KYMR trades at $114.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas KYMR's P/E ratio is -35.92. In terms of profitability, CAI's ROE is +0.19%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CAI is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for CAI.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CAI vs PRAX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PRAX trades at $334.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PRAX's P/E ratio is -25.88. In terms of profitability, CAI's ROE is +0.19%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, CAI is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PRAX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CAI vs CYTK Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CYTK trades at $73.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CYTK's P/E ratio is -10.22. In terms of profitability, CAI's ROE is +0.19%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, CAI is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for CAI.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CAI vs NUVL Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CAI's ROE is +0.19%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CAI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CAI.Check NUVL's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CAI vs IONS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while IONS trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas IONS's P/E ratio is -31.52. In terms of profitability, CAI's ROE is +0.19%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CAI is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for CAI.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CAI vs CRNX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CAI's ROE is +0.19%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CAI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CAI vs IMGN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CAI's ROE is +0.19%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CAI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
CAI vs ABVX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ABVX trades at $118.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ABVX's P/E ratio is -62.19. In terms of profitability, CAI's ROE is +0.19%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CAI is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ABVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CAI vs TXG Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TXG has a market cap of 8.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TXG trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TXG's P/E ratio is -116.25. In terms of profitability, CAI's ROE is +0.19%, compared to TXG's ROE of -0.09%. Regarding short-term risk, CAI is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TXG's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CAI vs PCVX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PCVX trades at $59.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PCVX's P/E ratio is -7.79. In terms of profitability, CAI's ROE is +0.19%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, CAI is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CAI vs BPMC Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CAI's ROE is +0.19%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CAI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CAI vs APGE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas APGE's P/E ratio is -31.19. In terms of profitability, CAI's ROE is +0.19%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CAI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CAI vs IBRX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while IBRX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas IBRX's P/E ratio is -8.15. In terms of profitability, CAI's ROE is +0.19%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, CAI is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CAI vs TGTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TGTX trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TGTX's P/E ratio is 19.53. In terms of profitability, CAI's ROE is +0.19%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, CAI is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CAI vs CERE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, CAI's ROE is +0.19%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CAI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CAI vs TWST Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TWST has a market cap of 7.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TWST trades at $127.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TWST's P/E ratio is -57.31. In terms of profitability, CAI's ROE is +0.19%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CAI is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CAI vs SYRE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while SYRE trades at $90.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas SYRE's P/E ratio is -46.46. In terms of profitability, CAI's ROE is +0.19%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, CAI is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for CAI.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CAI vs IMVT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while IMVT trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas IMVT's P/E ratio is -13.25. In terms of profitability, CAI's ROE is +0.19%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, CAI is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
CAI vs MTSR Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CAI's ROE is +0.19%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CAI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CAI vs RYTM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RYTM trades at $104.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RYTM's P/E ratio is -33.67. In terms of profitability, CAI's ROE is +0.19%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, CAI is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for CAI.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CAI vs BLTE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while BLTE trades at $173.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas BLTE's P/E ratio is -92.94. In terms of profitability, CAI's ROE is +0.19%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, CAI is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for CAI.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
CAI vs MRUS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CAI's ROE is +0.19%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CAI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CAI vs ACLX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CAI's ROE is +0.19%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CAI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CAI vs SRRK Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while SRRK trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas SRRK's P/E ratio is -16.06. In terms of profitability, CAI's ROE is +0.19%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, CAI is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for CAI.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CAI vs RETA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, CAI's ROE is +0.19%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CAI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
CAI vs CGON Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CGON trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CGON's P/E ratio is -26.90. In terms of profitability, CAI's ROE is +0.19%, compared to CGON's ROE of -0.25%. Regarding short-term risk, CAI is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for CAI.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CAI vs CNTA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CAI's ROE is +0.19%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CAI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CAI vs TVTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TVTX trades at $66.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TVTX's P/E ratio is -147.04. In terms of profitability, CAI's ROE is +0.19%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, CAI is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CAI vs MIRM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MIRM trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MIRM's P/E ratio is -6.75. In terms of profitability, CAI's ROE is +0.19%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, CAI is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for CAI.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CAI vs DNTH Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while DNTH trades at $106.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas DNTH's P/E ratio is -25.59. In terms of profitability, CAI's ROE is +0.19%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CAI is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for CAI.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CAI vs COGT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while COGT trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas COGT's P/E ratio is -15.83. In terms of profitability, CAI's ROE is +0.19%, compared to COGT's ROE of -0.73%. Regarding short-term risk, CAI is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CAI vs LGND Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while LGND trades at $284.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas LGND's P/E ratio is 31.23. In terms of profitability, CAI's ROE is +0.19%, compared to LGND's ROE of +0.20%. Regarding short-term risk, CAI is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for CAI.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CAI vs XENE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while XENE trades at $58.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas XENE's P/E ratio is -12.48. In terms of profitability, CAI's ROE is +0.19%, compared to XENE's ROE of -0.44%. Regarding short-term risk, CAI is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for CAI.Check XENE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CAI vs CDTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CAI's ROE is +0.19%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CAI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CAI vs ORKA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ORKA trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ORKA's P/E ratio is -47.62. In terms of profitability, CAI's ROE is +0.19%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, CAI is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
CAI vs ABCM Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CAI's ROE is +0.19%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CAI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ABCM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CAI vs PTCT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PTCT trades at $66.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PTCT's P/E ratio is -28.35. In terms of profitability, CAI's ROE is +0.19%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CAI is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PTCT's competition here
Erasca, Inc. (NASDAQ: ERAS)
CAI vs ERAS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ERAS trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ERAS's P/E ratio is -17.08. In terms of profitability, CAI's ROE is +0.19%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, CAI is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ERAS's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CAI vs ISEE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CAI's ROE is +0.19%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CAI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CAI vs APLS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas APLS's P/E ratio is 38.35. In terms of profitability, CAI's ROE is +0.19%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CAI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CAI vs DFTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while DFTX trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas DFTX's P/E ratio is N/A. In terms of profitability, CAI's ROE is +0.19%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, CAI is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CAI vs CRSP Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CRSP trades at $51.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CRSP's P/E ratio is -10.87. In terms of profitability, CAI's ROE is +0.19%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, CAI is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for CAI.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CAI vs EWTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while EWTX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas EWTX's P/E ratio is -24.00. In terms of profitability, CAI's ROE is +0.19%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, CAI is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CAI vs TERN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TERN's P/E ratio is -51.41. In terms of profitability, CAI's ROE is +0.19%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CAI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CAI vs ACAD Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ACAD trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ACAD's P/E ratio is 12.54. In terms of profitability, CAI's ROE is +0.19%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, CAI is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CAI vs FOLD Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CAI's ROE is +0.19%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CAI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CAI vs AKRO Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CAI's ROE is +0.19%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CAI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CAI.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CAI vs ALPN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CAI's ROE is +0.19%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CAI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
CAI vs PBLS Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PBLS trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PBLS's P/E ratio is -41.91. In terms of profitability, CAI's ROE is +0.19%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, CAI is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
CAI vs OPT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, CAI's ROE is +0.19%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CAI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CAI vs PRTC Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CAI's ROE is +0.19%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CAI is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for CAI.Check PRTC's competition here
Veradermics, Incorporated (NYSE: MANE)
CAI vs MANE Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MANE trades at $98.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MANE's P/E ratio is -31.52. In terms of profitability, CAI's ROE is +0.19%, compared to MANE's ROE of -0.38%. Regarding short-term risk, CAI is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for CAI.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CAI vs RLAY Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RLAY trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RLAY's P/E ratio is -12.02. In terms of profitability, CAI's ROE is +0.19%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, CAI is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for CAI.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CAI vs MRTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CAI's ROE is +0.19%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CAI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
CAI vs CELC Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CELC trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CELC's P/E ratio is -19.41. In terms of profitability, CAI's ROE is +0.19%, compared to CELC's ROE of -3.51%. Regarding short-term risk, CAI is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for CAI.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CAI vs ELVN Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ELVN trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ELVN's P/E ratio is -32.53. In terms of profitability, CAI's ROE is +0.19%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, CAI is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ELVN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CAI vs ADPT Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while ADPT trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas ADPT's P/E ratio is -59.02. In terms of profitability, CAI's ROE is +0.19%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, CAI is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
CAI vs TNGX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TNGX trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TNGX's P/E ratio is -28.65. In terms of profitability, CAI's ROE is +0.19%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, CAI is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CAI vs CPRX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CPRX's P/E ratio is 12.30. In terms of profitability, CAI's ROE is +0.19%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CAI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
CAI vs IOVA Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while IOVA trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas IOVA's P/E ratio is -11.78. In terms of profitability, CAI's ROE is +0.19%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, CAI is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for CAI.Check IOVA's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
CAI vs TLX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while TLX trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas TLX's P/E ratio is 117.85. In terms of profitability, CAI's ROE is +0.19%, compared to TLX's ROE of +0.07%. Regarding short-term risk, CAI is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CAI vs RYZB Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CAI's ROE is +0.19%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CAI is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RYZB's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CAI vs VKTX Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while VKTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas VKTX's P/E ratio is -6.86. In terms of profitability, CAI's ROE is +0.19%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, CAI is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check VKTX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CAI vs CBAY Comparison September 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 6.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CAI is priced at $24.34 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 68.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CAI's ROE is +0.19%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CAI is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CBAY's competition here